News Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
December 14, 2021- Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments in Healthy Human Subjects -
-
November 4, 2021- Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis -
-
November 1, 2021- Webcast to be Held at 8:00 am ET on November 4, 2021 -
-
October 28, 2021- Top-Line Data Expected in the Second Quarter of 2022 -
-
October 27, 2021- Represents the First Time Patients Will Be Treated With the Company's Potentially Best-In-Class RORγt Inverse Agonist -
-
October 14, 2021